Jubilant Ingrevia Ltd. · NSE:JUBLINGREA
Jubilant Ingrevia — Investor Presentation (February 2024)
35 slides from Jubilant Ingrevia's investor presentation, Feb 6, 2024
Slide 1: Intimation of Investor/Analyst Meetings
February 6, 2024 BSE Limited National Stock Exchange of India Limited Floor 25, P. J. Towers Exchange Plaza Dalal Street, Fort Bandra Kurla Complex Mumbai - 400 001 Bandra (E), Mumbai - 400 051 Scrip Code: 543271 Trading Symbol: JUBLINGREA Dear Sirs, Sub.: Intimation of Investor/ Analyst Meetings Pu
Slide 2: Enclosure of presentation and signature
We are also enclosing the presentation to be used during our interaction. This is for your information and record. Thanking you, Yours faithfully, For Jubilant Ingrevia Limited DEEPANJAL Digitally signed by DEEPANJALI GULATI I GULATI Date: 2024.02.06 17:48:42 +05'30' Deepanjali Gulati Company Secret
Slide 3: Investor Presentation February 2024
Investor Presentation February 2024 Jubilant Ingrevia Limited 1
Slide 4: Disclaimer
Disclaimer Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates f
Slide 5: Contents
Company Snapshot and Strategic Outlook - 04 Financial Highlights – Q3 & 9M’FY24 - 10 Business Segments Overview - 15 Strategic Initiatives Update - 25 Table of Contents 3
Slide 6: Company Overview
Company Overview Jubilant Ingrevia Limited 4
Slide 7: Jubilant Ingrevia – Overview
Jubilant Ingrevia – Overview 40+ years of legacy in Chemicals space, started in 1978 2300+ people with strong leadership team with average 25+ years of experience in Chemicals space Network of 5 state-of-art manufacturing facilities and 3 R&D centres with 100+ scientists Company overview and presenc
Slide 8: Integrated Business Segments
Integrated Business Segments Jubilant Ingrevia Limited Specialty Chemicals Nutrition & Health Solutions Chemical Intermediates • Pyridine & Picolines • Acetyls • Nutrition & Health Ingredients • Fine Chemicals • Specialty Ethanol • Agro Chemicals • Animal & Human Nutrition Health Solutions • Microbi
Slide 9: Jubilant Ingrevia Compass | Purpose, Vision, Capabilities & Values
Jubilant Ingrevia Compass |Purpose, Vision, Capabilities & Values Purpose Enable a Sustainable World through Chemistry Vision Leading provider of innovative solutions in our core chemistries globally Customer World-class, Innovation & ESG Leader People Centricity Safe Operations Technology Focused C
Slide 10: Company Snapshot
Company Snapshot 134+ Expertise in 35 technology products commercialized across platforms and multistep Catering to ~1600 customers product platforms i.e, Pyridine, chemistry With Top 10 customers Diketene, Acetyls, Nutrition and constituting 20% of business CDMO Geographical Mix Diverse Industry En
Slide 11: Executive Leadership Team
Executive Leadership Team Deepak Jain Chief Executive Officer & Managing Director 18 years of industry & Consulting experience Chandan Singh Ambrish Dixit Subhra Jyoti Roy Sumit Das Ashish Kumar Sinha Co-CEO President Sr. Vice President Sr. Vice President Vice President Chemical Intermediates Specia
Slide 12: Financial Highlights Q3 & 9M FY'24
Financial Highlights Q3 & 9M FY’24 10
Slide 13: Chairmen's Message on Q3'FY24 Financial Results
Chairmen’s Message on Q3’FY24 Financial Results Mr. Shyam S Bhartia Mr. Hari S Bhartia Chairman Co-Chairman “We are pleased to announce the stable business performance for Q3 amidst the continued challenging market condition. We are also glad to share that the Board has recommended an interim divide
Slide 14: Key Highlights | Q3'FY24
Key Highlights | Q3’FY24 • Specialty and Nutrition share of revenue • Initiative to increase renewable % in continued its upward traction at 54% in Product power usage progressing as per plan Q3FY24 Green/ESG • Bio certification of several products Portfolio mix • CDMO, Fine chemicals and Microbial
Slide 15: Financial Results Overview | Consolidated
Financial Results Overview | Consolidated Particulars1 Q3'FY23 Q2'FY24 Q3'FY24 Q-o-Q Y-o-Y 9M'FY23 9M'FY24 Y-o-Y Total Revenue 1,158 1,020 966 -5% -17% 3,628 3061 -16% Total EBITDA 158 126 104 -17% -34% 469 356 -24% EBITDA Margin (%) 14% 12% 11% 13% 12% Profit After Tax 92 57 39 -33% -58% 255 154 -4
Slide 16: Key Ratios | As on 31st December 2023
Key Ratios| As on 31st December 2023 1 Particulars FY’2023 Q2'FY2024 Q3'FY2024 Net Debt 312 701 636 Net Debt to Equity 0.12x 0.27x 0.23x Net Debt to EBITDA 0.54x 1.35x 1.36x Working Captal to Turnover 17% 23% 20% • The decrease in Net Debt was on account of working capital release driven by lean ini
Slide 17: Business Segments Overview
Business Segments Overview 15
Slide 18: Market & Business Highlights | Speciality Chemicals
Market & Business Highlights | Speciality Chemicals Market Highlights • Pharma end-use demand witnessed improvement, however pricing is yet to witness full recovery. • Agro Chemical slowdown continued on account of pipeline inventory and lower demand of end-use products and the overall market situat
Slide 19: Business Segment Overview | Speciality Chemicals
Business Segment Overview | Speciality Chemicals 70+ Products (Pyridines & Picolines, Globally among Top 2 Globally lowest cost Serving 15 of top 20 Cyanopyridines, in (Pyridine+Beta); producer of Pyridine Global Pharma & 7 of Piperidines, Globally #1 in 18 offering significant top 10 Global Aminopy
Slide 20: Financials | Speciality Chemicals Segment
Financials | Speciality Chemicals Segment Particulars1 Q3'FY23 Q2'FY24 Q3'FY24 Q-o-Q Y-o-Y 9M'FY23 9M'FY24 Y-o-Y Segment Revenue 468 382 365 -4% -22% 1,330 1110 -17% % Share of Overall Revenue 40% 37% 38% 37% 36% EBITDA 87 69 55 -20% -37% 229 181 -21% % EBITDA Margin 19% 18% 15% 17% 16% % Contributi
Slide 21: Market & Business Highlights | Nutrition & Health Solutions
Market & Business Highlights | Nutrition & Health Solutions Market Highlights • Vitamin demand remained stable during the quarter, however increased competition witnessed from Chinese suppliers. • Downstream industries continue to maintain lower inventories across regions and Niacinamide pricing rem
Slide 22: Business Segment Overview | Nutrition & Health Solutions
Business Segment Overview | Nutrition & Health Solutions Catering to Varied End Use Industries, ranging from, Personal Care, Nutraceuticals and Animal Feed & Human Nutrition Niainamide End Use Applications 5 Nutrition Ingredients & Global top 2 in Vitamin 18+ branded solutions Full Backward B3 (For
Slide 23: Financials | Nutrition & Health Solutions
Financials |Nutrition & Health Solutions 1 Particulars Q3'FY23 Q2'FY24 Q3'FY24 Q-o-Q Y-o-Y 9M'FY23 9M'FY24 Y-o-Y Segment Revenue 132 162 151 -7% 15% 396 516 30% % Share of Overall Revenue 11% 16% 16% 11% 17% EBITDA 9 19 17 -7% 101% 41 53 29% % EBITDA Margin 7% 12% 12% 10% 10% % Contribution to EBITD
Slide 24: Market & Business Highlights | Chemical Intermediates
Market & Business Highlights | Chemical Intermediates Market Highlights • Continued to witness muted demand in some of the downstream industries including Agrochemicals and Paracetamol. • End-Use Industries are maintaining low utilization and lower inventory levels. Business Highlights • New global
Slide 25: Business Segment Overview | Chemical Intermediates
Business Segment Overview | Chemical Intermediates Catering to Varied End Use Industries, most of these end use having promising growth 9 Products Acetic Anhydride: (Acetic Anhydride, Ethyl Globally No. 2 in Pharmaceuticals Artificial Sweeteners Agro Acetate ,Propionic Merchant Mkt Anhydride, Aldehy
Slide 26: Financial Highlights | Chemical Intermediates
Financial Highlights | Chemical Intermediates 1 Particulars Q3'FY23 Q2'FY24 Q3'FY24 Q-o-Q Y-o-Y 9M'FY23 9M'FY24 Y-o-Y Segment Revenue 559 476 450 -5% -19% 1,901 1436 -24% % Share of Overall Revenue 48% 47% 47% 52% 47% EBITDA 71 50 48 -4% -32% 224 159 -29% % EBITDA Margin 13% 11% 11% 12% 11% % Contri
Slide 27: Key Strategic Initiatives
Key Strategic Initiatives Jubilant Ingrevia Limited 25
Slide 28: Key Strategic Initiatives: Sustainability, RDT, Digitization
Key Strategic Initiatives • Biogenic Carbon Content study of our products conducted through C-14 testing and two of the products Sustainability received 100% rating and several products are 80% and above. • Completed Product Carbon Foot-printing (PCF) Assurance of 28 products covering 4 plants. • Ou
Slide 29: Sustainability
Sustainability Participated in S&P DJSI Assessment: Bharuch Nira Gajraula Global chemical industry's EHS initiative (Dec (Oct (Oct & Ethical framework towards safe chemicals • Achieved 95 percentile in the 2018) 2019) 2021) management and performance excellence Global Chemical Industry • Among the t
Slide 30: Research Development & Technology: Key Technology Platforms
Research Development & Technology (RDT) Newly setup R&D facility at Greater Noida, equipped with state-of-the-art technology, with advanced fume hoods and analytical machines to ensure efficient synthesis and reaction monitoring in a safer environment. Key Highlights 35 Key technology platforms deve
Slide 31: Efficiencies through Multi Location Manufacturing & Operation Excellence
Efficiencies through Multi Location Manufacturing & Operation Excellence Manufacturing Facilities 463 acres 310 acres 144 acres 109 acres 3.5 acres Gajraula, Uttar Pradesh, Bharuch, Gujarat, India India Speciality Chemicals, Integrated facility for Nutrition & Health Samlaya, Gujarat, India Ambernat
Slide 32: Bring Progressive Social Change via Strategic Multi-Stakeholder Partnerships
Bring Progressive Social Change via Strategic Multi-Stakeholder Partnerships Mission: To develop multi-stakeholder sustainable models to 1 Aspiring to touch the Lives Established Million bring about ‘social change’ involving knowledge generation through social initiatives in 2007 lives & sharing, ex
Slide 33: Annexure 1 - Income Statement | Consolidated
Annexure 1- Income Statement | Consolidated Particulars1 Q3'FY23 Q2'FY24 Q3'FY24 QoQ YoY 9M'FY23 9M'FY24 YoY Revenue from operations a) Sales/Income from operations 1153 1011 960 -5% -17% 3611 3040 -16% b) Other operating income 6 9 6 -33% 5% 17 21 27% Total revenue from operations 1158 1020 966 -5%
Slide 34: Annexure II: Income Statement Segmental – Q3 & 9M'FY24
Annexure II: Income Statement Segmental – Q3 & 9M‘FY24 Particulars1 Q3'FY23 Q2'FY24 Q3'FY24 QoQ (%) YoY (%) 9M'FY23 9M'FY24 YoY (%) Total Revenue from Operations 1,158 1,020 966 (5%) (17%) 3,628 3,061 (16%) Speciality Chemicals 468 382 365 (4%) (22%) 1,330 1,110 (17%) Nutrition & Health Solutions 13
Slide 35: Thank you for your time
For More Information For Investors: Jubilant Ingrevia Limited is a global integrated Life Science products and Innovative Solutions provider serving Pavleen Taneja Pharmaceutical, Nutrition, Agrochemical, Consumer and Jubilant Ingrevia Limited. Industrial customers with customised products and solut
Jubilant Ingrevia — Investor Presentation (February 2024) on 6ix